Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05682482
PHASE3

LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.

Sponsor: M. Medici

View on ClinicalTrials.gov

Summary

Hypothyroidism is common, affecting 5% of the general population, for which levothyroxine (LT4) monotherapy is the standard treatment. Despite normalized serum thyroid hormone levels, 10-15% of LT4 treated patients have various persistent complaints, the most important of which is tiredness. This could be explained by the fact that physiological T4/T3 ratios cannot be reached with LT4 monotherapy, as in a healthy individual T3 is not only derived from T4/T3 conversion but is also directly produced by the thyroid itself. Studies have reported contradicting results as to whether addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy is effective or not. Studies have suggested higher effectiveness in patients carrying genetic variation in the type 2 deiodinase (DIO2-rs225014) and monocarboxylate transporter 10 (MCT10-rs17606253) genes. Objective: To investigate whether addition of liothyronine (LT4/LT3 combination therapy) in in patients with persistent tiredness on LT4 monotherapy is effective or not in relieving tiredness.

Official title: A National Randomized Placebo-controlled Double-blind Multicenter Trial of LT4/LT3 Combination Therapy in Patients with Autoimmune Hypothyroidism: the T3-4-Hypo Trial.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

600

Start Date

2022-10-07

Completion Date

2028-01

Last Updated

2025-02-26

Healthy Volunteers

No

Interventions

DRUG

LT3 (liothyronine)

Addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy. To investigate whether addition of LT3 is effective in relieving tiredness.

DRUG

Placebo

Addition of placebo (LT4 monotherapy) in patients with persistent tiredness on LT4 monotherapy.

Locations (19)

Flevoziekenhuis

Almere Stad, Netherlands

Amsterdam UMC - Location AMC

Amsterdam, Netherlands

Gelre ziekenhuizen

Apeldoorn, Netherlands

Rijnstate

Arnhem, Netherlands

Amphia ziekenhuis

Breda, Netherlands

Van Weel-Bethesda Hospital

Dirksland, Netherlands

Albert Schweitzer Hospital

Dordrecht, Netherlands

Treant

Emmen, Netherlands

Admiraal de Ruyter Hospital

Goes, Netherlands

University Medical Center Groningen

Groningen, Netherlands

Saxenburgh MC

Hardenberg, Netherlands

Radboudumc

Nijmegen, Netherlands

Erasmus Medical Center

Rotterdam, Netherlands

Maasstad Hospital

Rotterdam, Netherlands

Franciscus Gasthuis & Vlietland

Schiedam, Netherlands

Zuyderland

Sittard, Netherlands

University Medical Center Utrecht

Utrecht, Netherlands

Maxima Medical Center

Veldhoven, Netherlands

Vie Curie MC

Venlo, Netherlands